Experimental therapeutics: targeting the redox Achilles heel of cancer

Area of Science:

• Oncology and Pharmacology
• Redox Biology and Cancer Therapeutics

Background:

• Reactive oxygen species (ROS) signaling is crucial for cancer cell proliferation and survival.
• Elevated oxidative stress in cancer cells presents a unique therapeutic vulnerability.
• Redox-modulating agents offer a promising strategy for selective cancer treatment.

Purpose of the Study:

• To review small-molecule anticancer redox drugs in preclinical and clinical development.
• To discuss the mechanisms of action of novel redox-targeting chemotherapeutics.
• To explore the potential of redox biomarkers for guiding personalized cancer therapy.

Main Methods:

• Review of current literature on small-molecule anticancer redox drugs.
• Categorization of drugs based on their mechanisms targeting cancer redox systems.
• Discussion of preclinical and clinical development status of these agents.

Main Results:

• Several classes of redox-modulating drugs are under investigation, including superoxide dismutase/catalase mimetics, pro-oxidant catalysts, metal-based pro-oxidants, hypoxia-selective agents, and antagonists of glutathione/thioredoxin systems.
• These agents exhibit diverse mechanisms to exploit cancer cell redox imbalances.
• Ongoing research in redox biomarker discovery is crucial for patient selection.

Conclusions:

• Small-molecule redox drugs represent a promising frontier in cancer therapy.
• Targeting the specific redox vulnerabilities of tumors offers a selective approach.
• Future redox phenotyping and genotyping will personalize the selection of redox chemotherapeutics.